<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761770</url>
  </required_header>
  <id_info>
    <org_study_id>20-522</org_study_id>
    <nct_id>NCT04761770</nct_id>
  </id_info>
  <brief_title>Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders</brief_title>
  <official_title>Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether a geriatric assessment can lead to better treatment outcomes&#xD;
      in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia,&#xD;
      ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are&#xD;
      going to receive chemotherapy or another treatment to prepare the body for an allogeneic&#xD;
      hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at&#xD;
      patients' cognitive function (thinking processes), physical function, mobility (ability to&#xD;
      move the body), mood, nutrition, and current medications to help decide the type of treatment&#xD;
      they'll receive.&#xD;
&#xD;
      Another purpose of this study is to see whether use of the geriatric assessment improves&#xD;
      participants' quality of life. We will evaluate participants' quality of life through&#xD;
      questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized&#xD;
      allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The&#xD;
      less vulnerable/fit older patients are recommended to receive MA conditioning and the more&#xD;
      vulnerable older patients are recommended to receive RIC/NMA conditioning.&#xD;
&#xD;
        1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -&gt; MA regimen&#xD;
&#xD;
        2. HCT-CI/Age &gt;4 AND/OR any IADL impairment (more vulnerable) -&gt; RIC/NMA regimen&#xD;
&#xD;
             -  Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa,&#xD;
                clofarabine&#xD;
&#xD;
             -  Radiation therapy: total body irradiation (TBI)&#xD;
&#xD;
             -  Other therapy: anti-thymocyte globulin (ATG)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single center, phase II pilot treatment-allocation study at MSK for older patients considering allogeneic hematopoietic cell transplantation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence of non-relapse mortality (NRM)</measure>
    <time_frame>1 year</time_frame>
    <description>defined as death in the absence of relapse/disease progression.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasms</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Atypical Chronic Myeloid Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Overlapping Syndrome</condition>
  <arm_group>
    <arm_group_label>Geriatric participants with various blood disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geriatric assessment (GA) pre-transplant&#xD;
Risk-adapted allocation of conditioning intensity based on GA&#xD;
GA-directed, longitudinal supportive care management</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatric assessment (GA) pre-transplant</intervention_name>
    <description>Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.</description>
    <arm_group_label>Geriatric participants with various blood disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conditioning regimen</intervention_name>
    <description>Based on the Geriatric assessment.&#xD;
HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -&gt; Myeloablative (MA) regimen&#xD;
HCT-CI/Age &gt;4 AND/OR any IADL impairment (more vulnerable) -&gt; Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen</description>
    <arm_group_label>Geriatric participants with various blood disorders</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic CD34+ selected stem cells</intervention_name>
    <description>Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.</description>
    <arm_group_label>Geriatric participants with various blood disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are 60 years or older&#xD;
&#xD;
          -  have a pathologically confirmed myeloid malignancies including acute myeloid leukemia,&#xD;
             ,myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders&#xD;
             including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and&#xD;
             myelodysplastic/myeloproliferative overlapping syndrome&#xD;
&#xD;
          -  have &lt;10% blasts in bone marrow prior to transplant&#xD;
&#xD;
          -  have a matched related or unrelated donor, mismatched unrelated donor, or&#xD;
             haploidentical donor&#xD;
&#xD;
          -  Meet institutional standard criteria for allogeneic transplantation as determined by&#xD;
             the primary transplant physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior hematopoietic cell transplantation&#xD;
&#xD;
          -  Cord blood donors&#xD;
&#xD;
          -  Persons with active, refractory disease defined by ≥10% blasts in bone marrow prior to&#xD;
             transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard J Lin, MD, PhD</last_name>
    <phone>646-608-2646</phone>
    <email>linr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roni Tamari, MD</last_name>
    <phone>646-608-3738</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent Only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent Only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent Only)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (Consent Only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard j Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent Only)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood disorders</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplant</keyword>
  <keyword>20-522</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

